RIDGEFIELD, Conn. and
INDIANAPOLIS, Sept. 12, 2017 /PRNewswire/ -- New analyses
of the landmark EMPA-REG OUTCOME® trial showed that
Jardiance® (empagliflozin) tablets reduced the risk of
cardiovascular death in adults with type 2 diabetes and established
cardiovascular disease, independent of blood sugar control at the
start of the study. A reduction in cardiovascular death was also
seen when Jardiance was added to common first and second-line
diabetes medications, such as metformin or sulfonylurea. These
results from post-hoc analyses were presented by Boehringer
Ingelheim and Eli Lilly and Company (NYSE: LLY) at the
53rd Annual Meeting of the European Association for the
Study of Diabetes (EASD) in Lisbon,
Portugal.
"Now that we have a new option for reducing the risk of
cardiovascular death among adults with type 2 diabetes, we are
striving to better understand if there are differences in how
adults with type 2 diabetes can benefit," said Silvio Inzucchi, M.D., professor of medicine,
Yale School of Medicine, who presented
the data today. "These new analyses of the EMPA-REG OUTCOME trial
showed empagliflozin was effective in reducing the risk of
cardiovascular death in adults with type 2 diabetes and established
cardiovascular disease, no matter what the blood sugar levels at
the start of the study were or if empagliflozin was added to
commonly used oral blood sugar lowering treatments."
In all four blood sugar level groups at study start (A1C levels
of <7.0 percent, 7.0 percent to <8.0 percent, 8.0 percent to
<9.0 percent and ≥9.0 percent), patients receiving
Jardiance demonstrated a reduction in the risk of
cardiovascular death compared with placebo. This was consistent
with the risk reduction seen in the overall trial population and
seen irrespective of whether blood sugar control was improved
following introduction of the study treatment (as measured by a
decrease in A1C level of ≥ 0.5 percent at week 12).
Additional post-hoc analyses showed that when Jardiance was
added to metformin or sulfonylurea, the reduction of cardiovascular
death compared with placebo was consistent with the overall trial
population. These analyses also showed the proportion of patients
with hypoglycemic side effects were similar between the placebo and
Jardiance groups in the EMPA-REG OUTCOME trial.
Jardiance is the first and only oral type 2 diabetes medicine
approved to reduce the risk of cardiovascular death in adults with
type 2 diabetes and established cardiovascular disease. The
landmark EMPA-REG OUTCOME trial demonstrated that Jardiance reduced
the risk of cardiovascular death by 38 percent versus placebo in
people with type 2 diabetes and established cardiovascular disease
when added to standard of care (including glucose-lowering agents
and cardiovascular drugs). The overall safety profile of Jardiance
in EMPA-REG OUTCOME was consistent with that of previous studies of
Jardiance and current label information.
"Cardiovascular disease remains the leading cause of death in
people with type 2 diabetes and contributes significantly to the
burden of diabetes care," said David
Kendall, M.D., distinguished medical fellow, Lilly Diabetes.
"The results presented at EASD add further evidence of the benefit
Jardiance can provide to adults with type 2 diabetes with different
background blood sugar control."
"Boehringer Ingelheim and Lilly are committed to advancing the
understanding of the EMPA-REG OUTCOME data to help physicians
better tailor their treatment approach, since proper type 2
diabetes management requires a personalized plan," said
Rogelio Braceras, M.D., therapeutic
area head, Clinical Development & Medical Affairs, Metabolism,
Boehringer Ingelheim Pharmaceuticals, Inc. "We're pleased that
Jardiance's life-saving cardiovascular benefit to reduce the risk
of cardiovascular death was consistent in the trial regardless of
the baseline variables we tested, including blood sugar
levels."
About Diabetes and Cardiovascular Disease
Approximately 30 million Americans and an estimated 415 million
people worldwide have diabetes, and nearly 24 percent of Americans
with diabetes—or more than 7 million people—are undiagnosed. In the
U.S., approximately nine percent of those aged 18 and older have
diabetes. Type 2 diabetes is the most common type, accounting for
an estimated 90 to 95 percent of all diagnosed adult diabetes cases
in the U.S. Diabetes is a chronic condition that occurs when the
body does not properly produce or use the hormone insulin.
Due to the complications associated with diabetes, such as high
blood sugar, high blood pressure and obesity, cardiovascular
disease is a major complication and the leading cause of death
associated with diabetes. People with diabetes are two to four
times more likely to develop cardiovascular disease than people
without diabetes. Approximately 50 percent of deaths in people with
type 2 diabetes worldwide and approximately two-thirds of deaths in
people with type 2 diabetes in the U.S. are caused by
cardiovascular disease. In the U.S., healthcare costs for managing
cardiovascular conditions in patients with diabetes totaled more
than $23 billion in 2012.
Having a history of diabetes at age 60 can shorten a person's
lifespan by as much as six years compared with someone without
diabetes. And having both diabetes and a history of heart attack or
stroke at age 60 can shorten a person's lifespan by as much as 12
years compared with someone without these conditions.
About the EMPA-REG OUTCOME Trial
(NCT01131676)
EMPA-REG OUTCOME was a
long-term, multicenter, randomized, double-blind,
placebo-controlled trial of more than 7,000 patients from 42
countries with type 2 diabetes and established cardiovascular
disease.
The study assessed the effect of Jardiance (10 mg or 25 mg once
daily) added to standard of care compared with placebo added to
standard of care. Standard of care was comprised of
glucose-lowering agents and cardiovascular drugs (including for
blood pressure and cholesterol). The primary endpoint was defined
as time to first occurrence of cardiovascular death, non-fatal
heart attack or non-fatal stroke.
The overall safety profile of Jardiance was consistent with that
of previous trials.
About Educational Initiatives
Given the critical
connection between diabetes and cardiovascular disease, Boehringer
Ingelheim and Eli Lilly and Company are committed to providing a
wide range of diabetes therapies along with programs and support to
raise awareness, understanding and action toward reducing the
impact of cardiovascular disease in people with type 2
diabetes.
What is JARDIANCE? (www.jardiance.com)
JARDIANCE is a prescription medicine used along with diet and
exercise to lower blood sugar in adults with type 2 diabetes.
JARDIANCE is also used to reduce the risk of cardiovascular
death in adults with type 2 diabetes who have known cardiovascular
disease.
JARDIANCE is not for people with type 1 diabetes or for people
with diabetic ketoacidosis (increased ketones in the blood or
urine).
IMPORTANT SAFETY INFORMATION
What is the most important information I should
know about JARDIANCE?
JARDIANCE can cause serious side effects, including:
- Dehydration. JARDIANCE can cause some people to have
dehydration (the loss of body water and salt). Dehydration may
cause you to feel dizzy, faint, light-headed, or weak, especially
when you stand up.
You
may be at a higher risk of dehydration if you:
- have low blood pressure
- take medicines to lower your blood pressure including water
pills (diuretics)
- are on a low salt diet
- have kidney problems
- are 65 years of age or older.
- Ketoacidosis (increased ketones in your blood or urine).
Ketoacidosis is a serious condition and may need to be treated in
the hospital. Ketoacidosis may lead to death. Ketoacidosis occurs
in people with type 1 diabetes and can also occur in people with
type 2 diabetes taking JARDIANCE, even if blood sugar is less than
250 mg/dL. Stop taking JARDIANCE and call your doctor right away
if you get any of the following symptoms, and if possible,
check for ketones in your urine:
-
- nausea
- vomiting
- stomach-area (abdominal) pain
- tiredness
- trouble breathing
- Serious urinary tract infections. Serious urinary tract
infections can occur in people taking JARDIANCE and may lead to
hospitalization. Tell your doctor if you have symptoms of a urinary
tract infection such as a burning feeling when passing urine, a
need to urinate often or right away, pain in the lower part of your
stomach or pelvis, or blood in the urine. Sometimes people also may
have a fever, back pain, nausea or vomiting.
- Vaginal yeast infection. Women who take JARDIANCE may
get vaginal yeast infections. Talk to your doctor if you experience
vaginal odor, white or yellowish vaginal discharge (discharge may
be lumpy or look like cottage cheese), and/or vaginal itching.
- Yeast infection of the penis. Men who take JARDIANCE may
get a yeast infection of the skin around the penis, especially
uncircumcised males and those with chronic infections. Talk to your
doctor if you experience redness, itching or swelling of the penis,
rash of the penis, foul smelling discharge from the penis, and/or
pain in the skin around penis.
Who should not take JARDIANCE?
Do not
take JARDIANCE if you are allergic to empagliflozin or any of
the ingredients in JARDIANCE. Symptoms of serious allergic
reactions to JARDIANCE may include:
- skin rash
- raised red patches on your skin (hives)
- swelling of the face, lips, tongue, and throat that may cause
difficulty breathing or swallowing.
If you have any of these symptoms, stop taking JARDIANCE and
contact your doctor or go to the nearest emergency room right
away.
Do not take JARDIANCE if you have severe kidney problems
or are on dialysis.
What should I tell my doctor before using
JARDIANCE?
Tell your doctor if you:
- have kidney problems. Your doctor may do blood tests to check
your kidneys before and during your treatment with JARDIANCE
- have liver problems
- have a history of urinary tract infections or problems with
urination
- are going to have surgery
- are eating less due to illness, surgery, or a change in your
diet
- have or have had problems with your pancreas, including
pancreatitis or surgery on your pancreas
- drink alcohol very often, or drink a lot of alcohol in the
short term ("binge" drinking)
- have any other medical conditions
- are pregnant or planning to become pregnant. It is unknown if
JARDIANCE will harm your unborn baby
- are breastfeeding, or plan to breastfeed. It is unknown if
JARDIANCE passes into your breast milk.
Tell your doctor about all the medicines you take
including prescription and over-the-counter medicines, vitamins,
and herbal supplements. Especially tell your doctor if you take
water pills (diuretics) or medicines that can lower your blood
sugar such as insulin.
What are other possible side effects of
JARDIANCE?
- Low blood sugar (hypoglycemia): if you take
JARDIANCE with another medicine that can cause low blood sugar,
such as sulfonylurea or insulin, your risk of low blood sugar is
higher. The dose of your sulfonylurea or insulin may need to be
lowered. Symptoms of low blood sugar may include:
-
- Headache
- Drowsiness
- Weakness
- Dizziness
- Confusion
- Irritability
- Hunger
- Fast heartbeat
- Sweating
- Shaking or feeling jittery
- Kidney Problems. Sudden kidney injury has happened in
people taking JARDIANCE. Talk to your doctor right away if you
reduce the amount you eat or drink, or if you lose liquids; for
example, from vomiting, diarrhea, or being in the sun too long.
- Increased fats in your blood (cholesterol).
The most common side effects of JARDIANCE
include urinary tract infections, and yeast infections in
females.
You are encouraged to report negative side
effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or
call 1-800-FDA-1088.
For more information, please see full Prescribing Information
and Patient Information.
JAR CONS ISI 1.11.17
Boehringer Ingelheim and Eli Lilly and Company
In
January 2011, Boehringer Ingelheim
and Eli Lilly and Company announced an alliance in diabetes that
centers on compounds representing several of the largest diabetes
treatment classes. This alliance leverages the strengths of two of
the world's leading pharmaceutical companies. By joining forces,
the companies demonstrate commitment in the care of patients with
diabetes and stand together to focus on patient needs. Find out
more about the alliance at www.boehringer-ingelheim.com or
www.lilly.com.
About Boehringer Ingelheim
Boehringer Ingelheim
Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary
of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical
companies. Headquartered in Ingelheim, Germany, the company operates globally with
approximately 50,000 employees. Since its founding in 1885, the
company has remained family-owned and today creates value through
innovation for three business areas including human
pharmaceuticals, animal health and biopharmaceutical contract
manufacturing.
Boehringer Ingelheim is committed to improving lives and
providing valuable services and support to patients and their
families. Our employees create and engage in programs that
strengthen our communities. Please visit our website to learn more
about how we make more health for more people through our Corporate
Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about
$17.6 billion (15.9 billion euros). R&D expenditure
corresponds to 19.6 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us,
or follow us on Twitter @BoehringerUS.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we
introduced the world's first commercial insulin. Today we are
building upon this heritage by working to meet the diverse needs of
people with diabetes and those who care for them. Through research
and collaboration, a wide range of therapies and a continued
determination to provide real solutions—from medicines to support
programs and more—we strive to make life better for all those
affected by diabetes around the world. For more information, visit
www.lillydiabetes.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us
at www.lilly.com and newsroom.lilly.com/social-channels.
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about Jardiance and its safety profile, and reflects
Lilly's current belief. However, as with any pharmaceutical
product, there are substantial risks and uncertainties in the
process of development and commercialization. Among other things,
there can be no guarantee that future study results will be
consistent with the results to date or that Jardiance will receive
additional regulatory approvals. For further discussion of these
and other risks and uncertainties, see Lilly's most recent Form
10-K and Form 10-Q filings with the United States Securities and
Exchange Commission. Except as required by law, Lilly undertakes no
duty to update forward-looking statements to reflect events after
the date of this release.
Jardiance® and EMPA-REG OUTCOME® are
registered trademarks of Boehringer Ingelheim.
P-LLY
MPR-US-100057
CONTACT:
Lauren Murphy,
MBA
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: lauren.murphy@boehringer-ingelheim.com
Phone: (203) 448-1982
Grant
Smith
Communications
Lilly Diabetes
Email: grant.smith@lilly.com
Phone: (317) 954-9907
View original content with
multimedia:http://www.prnewswire.com/news-releases/jardiance-empagliflozin-tablets-reduced-risk-of-cardiovascular-death-in-people-with-type-2-diabetes-and-established-cardiovascular-disease-independent-of-background-blood-sugar-control-300517404.html
SOURCE Eli Lilly and Company; Boehringer Ingelheim